NewsMartindale Pharma enters wound care market with an intelligent new option for rapid wound bed preparation

Martindale Pharma enters wound care market with an intelligent new option for rapid wound bed preparation

Complex wounds, Exudate Management, Products

Martindale Pharma enters wound care market with an intelligent new option for rapid wound bed preparationThis month, Martindale Pharma is launching its first product for the wound care market. Established over 100 years ago in the UK, Martindale Pharma is a UK-based company with a reputation as a market leader in the development and manufacture of innovative medicine, which help healthcare professionals in their roles.

Understanding the needs and challenges faced by clinicians is key to our product development, and we believe that our new wound care range will help to make a difference both to your practice and patient outcomes.

Drawtex®, our first product in this area, offers an intelligent advance in wound bed preparation. Drawtex® is a novel hydroconductive wound dressing based on patented LevaFiber™ technology, which applies the latest thinking in materials technology and offers a new perspective in handling exudate and reducing slough and necrotic tissue. It has a capacity to:

  • Reduce excess exudate1
  • Remove biofilm nutrients2
  • Reduce inflammation2
  • Loosen slough2
  • Reduce bacterial bioburden2
  • Decrease deleterious cytokines in the wound bed3.

The LevaFiber™ technology combines absorbent, cross-action structures that enable the dressing to draw large volumes of exudate and other debris from the wound and through the dressing. This hydroconductive debridement allows Drawtex® to lift, hold and transfer exudate both vertically and horizontally into the body of the dressing, where it can absorb five times its own weight.

 

Clinically, results have shown that Drawtex® can decrease wound exudate, tissue bacterial levels, nutrients for biofilm production and deleterious cytokine levels such as matrix metalloproteinases (MMP-1 and MMP-9)1, 4, 5. Based on these actions, Drawtex® facilitates effective wound bed preparation and kick-starts healing, which makes it a possible alternative to passive absorptive products, like calcium alginates, hydrofibers, foams and superabsorbers6. On occasions, it has also been seen to be able to replace some enzymatic, antimicrobial and negative-pressure wound therapy (NPWT)7 .

It also offers benefits both to healthcare professionals and patients in that it can be cut and tailored to any anatomical location, layered to manage heavily exuding wounds, and will not shed fibres or fall apart, even when soaked.

For more details about this innovative portfolio of products and to meet the team, please come to stand 62 at the Wounds UK conference in Harrogate.

Contact details: Martindale Pharma, Hubert Road, Brentwood, Essex CM14 4JY; www.martindalepharma.co.uk

References

1. Ochs D, Uberti G, Donate GA, Abercrombie M, Mannari RJ, Payne WG (2012) Evaluation of Mechanisms of Action of a Hydroconductive Wound Dressing (Drawtex) in Chronic Wounds. Supplement to Wounds September 2012

2. Wolcott R, Dowd S (2011) Drawtex effects on VLU healing and biofilm. Poster Presentation Symposium on Advanced Wound Care (SAWC), 2011

3. Lichtenstein P, Wendelekn M, Alvarez OM (2011) Detoxification of venous ulcers with a novel hydroconductive wound dressing that transfers chronic wound fluid away from the wound. Poster presentation at the Symposium on Advanced Wound Care. Dallas, Texas April 2011

4. Couch KS (2012) Discovering hydroconductive dressings. Ostomy Wound Manage 58(4): 8-10

5. Wolcott RD (2012) The effects of a hydroconductive dressing on the suppression of wound biofilm. Wounds 24(5): 132-7

6. Spruce P (2012) Preparing the wound to heal using a new hydroconductive dressing. Ostomy Wound Manage 58(7): 2-3

7. Scott RG (2012) A hydroconductive dressing as a potential alternative to negative pressure wound therapy. Ostomy Wound Manage May 2012